Dupilumab/Dalbitur begins to take effect after a few injections

Dupilumab (dupilumab) is an innovative humanized monoclonal antibody that improves a variety of chronic inflammatory diseases by targeting the inhibition of the interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways. For patients, one of the most concerning issues is “how many injections will it take to see obvious effects”. According to overseas clinical and real-world research experience, most patients can see significant relief of symptoms within 4 to 8 weeks after continuous medication, and some individuals can even feel improvement in skin itching, inflammation or respiratory symptoms after the first two injections. The speed at which the drug takes effect varies depending on the type of disease, individual differences and immune status.

In the treatment of atopic dermatitis, dupilumab can usually significantly reduce the area of rash and itching around the 4th week; for patients with chronic sinusitis associated with nasal polyps, nasal congestion is generally reduced and the sense of smell is improved within 6 to 12 weeks; and for asthma patients, long-term use can significantly reduce the frequency of acute attacks and improve lung function after 2 to 3 months. It should be noted that dupilumab is a long-term immunomodulatory drug, and its efficacy relies on continuous suppression of inflammatory pathways. Therefore, it should be used regularly on a regular basis and should not be discontinued due to short-term improvement.

From the perspective of immune mechanism, dupilumab blocks IL-4Rα receptor subunit, inhibits Th2 type immune response, reduces eosinophils and IgE levels, thereby alleviating chronic allergic inflammation. With the suppression of inflammatory factors, the skin or respiratory tract barrier function is gradually restored, and clinical symptoms will be steadily improved. Therefore, the effect is not instantaneous, but a gradual immune repair process. Doctors usually recommend that patients maintain regular monitoring during the early stages of medication, including skin assessment, respiratory function testing or laboratory inflammation indicators, in order to promptly judge the efficacy and adjust the dosage.

Reference materials:https://www.drugs.com